Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

The objective of this study was to evaluate the evidence on cost‐effectiveness of
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …

Children and adolescents with Crohn's disease (CD) present often with a more complicated
disease course compared to adult patients. In addition, the potential impact of CD on growth …

Pharmacogenetics (PGx) has the potential to personalize pharmaceutical treatments. Many
relevant gene–drug associations have been discovered, but PGx-guided treatment needs to …

Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially
targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis …

Background Pharmacogenetics offers the potential to improve health outcomes by
identifying individuals who are at greater risk of harm from certain medicines. Routine …

AIM Probably, the most important and potentially lethal adverse event of azathioprine (AZA)
and mercaptopurine (MP) is myelosuppression. Our aim was to conduct a review of AZA/MP …

Background Inflammatory bowel disease (IBD) is a chronic disease placing a large health
and economic burden on health systems worldwide. The treatment landscape is complex …

Objective Due to extended application of pharmacogenetic and pharmacogenomic
screening (PGx) tests it is important to assess whether they provide good value for money …

The implementation of genetic data for a better prediction of response to medications and
adverse drug reactions is becoming a reality in some clinical fields. However, to be …